<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gao X</submitter><funding>Heilongjiang Graduate Excellence Funding Program</funding><funding>National Natural Science Foundation of China</funding><funding>the Natural Science Foundation of Heilongjiang</funding><pagination>e05270</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12631900</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(43)</volume><pubmed_abstract>The clinical utility of the anticancer agent doxorubicin (DOX) is limited by its dose-dependent cardiotoxicity. ALYREF, a nuclear protein that preserves genomic stability through interactions with intranuclear components or as an m⁵C-binding regulator of mRNA maturation and export, has not been previously implicated in DOX-induced cardiotoxicity (DIC). Here, the role and underlying mechanisms of ALYREF in the pathogenesis of DIC are investigated. The findings demonstrate that ALYREF expression is markedly reduced in a murine model of DIC. Myocardial-specific overexpression of ALYREF attenuates DOX-induced DNA damage and cardiomyocyte apoptosis, whereas cardiac-specific knockout of ALYREF (ALYREF CKO) exacerbates DOX-induced cardiac dysfunction. Mechanistically, it is identified that nuclea</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>Preservation of ALYREF Phase Separation Mitigates Doxorubicin-Induced Cardiomyocyte DNA Damage and Cardiotoxicity.</pubmed_title><pmcid>PMC12631900</pmcid><funding_grant_id>82400418</funding_grant_id><funding_grant_id>PL2024H083</funding_grant_id><funding_grant_id>LJYXL2024-072</funding_grant_id><funding_grant_id>ZL2024H017;PL2024H083</funding_grant_id><funding_grant_id>82373958</funding_grant_id><funding_grant_id>ZL2024H017</funding_grant_id><funding_grant_id>82470266</funding_grant_id><funding_grant_id>82500435</funding_grant_id><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Yu L</pubmed_authors><pubmed_authors>Pan Z</pubmed_authors><pubmed_authors>Gong R</pubmed_authors><pubmed_authors>Xiao Z</pubmed_authors><pubmed_authors>Ren Z</pubmed_authors><pubmed_authors>Yang B</pubmed_authors><pubmed_authors>Han Z</pubmed_authors><pubmed_authors>Ma W</pubmed_authors><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Cai B</pubmed_authors><pubmed_authors>Cai A</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Lian G</pubmed_authors><pubmed_authors>Tian Y</pubmed_authors><pubmed_authors>Zagidullin N</pubmed_authors><pubmed_authors>Gao X</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Shen Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Preservation of ALYREF Phase Separation Mitigates Doxorubicin-Induced Cardiomyocyte DNA Damage and Cardiotoxicity.</name><description>The clinical utility of the anticancer agent doxorubicin (DOX) is limited by its dose-dependent cardiotoxicity. ALYREF, a nuclear protein that preserves genomic stability through interactions with intranuclear components or as an m⁵C-binding regulator of mRNA maturation and export, has not been previously implicated in DOX-induced cardiotoxicity (DIC). Here, the role and underlying mechanisms of ALYREF in the pathogenesis of DIC are investigated. The findings demonstrate that ALYREF expression is markedly reduced in a murine model of DIC. Myocardial-specific overexpression of ALYREF attenuates DOX-induced DNA damage and cardiomyocyte apoptosis, whereas cardiac-specific knockout of ALYREF (ALYREF CKO) exacerbates DOX-induced cardiac dysfunction. Mechanistically, it is identified that nuclea</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T17:07:35.571Z</modification><creation>2026-05-19T03:12:02.861Z</creation></dates><accession>S-EPMC12631900</accession><cross_references><pubmed>40899520</pubmed><doi>10.1002/advs.202505270</doi></cross_references></HashMap>